Research Analysts Set Expectations for APLS FY2026 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($0.80) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $44.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.

A number of other brokerages have also weighed in on APLS. Scotiabank decreased their price objective on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a report on Thursday, May 8th. Citigroup decreased their target price on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 22nd. Wedbush dropped their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Needham & Company LLC decreased their price objective on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Nine equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $40.05.

Apellis Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ APLS traded up $0.19 during trading on Tuesday, reaching $19.58. The company had a trading volume of 1,720,668 shares, compared to its average volume of 2,316,749. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $43.76. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The business's 50-day moving average is $18.40 and its 200 day moving average is $25.53. The stock has a market cap of $2.46 billion, a PE ratio of -9.65 and a beta of 0.68.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. During the same period in the prior year, the company earned ($0.54) earnings per share. The firm's quarterly revenue was down 3.2% compared to the same quarter last year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its holdings in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after acquiring an additional 758 shares during the period. Signaturefd LLC grew its stake in Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after purchasing an additional 918 shares in the last quarter. Assetmark Inc. grew its stake in Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock worth $27,000 after purchasing an additional 1,221 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Apellis Pharmaceuticals during the 4th quarter worth about $83,000. Finally, US Bancorp DE raised its position in Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after purchasing an additional 1,327 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).